Scientists at Northwestern Medicine have engineered a microscopic delivery system that hunts down and eliminates the molecular saboteurs driving disease—one mutant protein at a time. The innovation, described in Nature Communications, represents a fundamentally new approach to treating cancers and genetic disorders by harnessing the body's own cellular machinery to dispose of disease-causing proteins.
The breakthrough centers on synthetic biomolecular condensates—engineered structures that mimic the membrane-less organelles cells naturally create to organize molecular activity. Shana Kelley, the Neena B. Schwartz Professor of Chemistry, Biomedical Engineering, and Biochemistry and Molecular Genetics at Northwestern Medicine, and her team combined these condensates with antibodies designed to recognize specific disease proteins, creating what amounts to a cellular assassin that can slip into cells and target its prey with precision.
The team focused on KRAS, a notorious oncogenic protein that drives many human cancers. What makes KRAS particularly challenging is how subtly disease often hides within its structure—sometimes a single amino acid difference separates the harmful mutated version from the benign wild-type version. This is where the research becomes remarkable. When Northwestern researchers paired their biomolecular condensates with an antibody designed to recognize KRAS G12V, a specific cancer-causing mutation, the system could distinguish between the two and degrade only the dangerous version, leaving healthy proteins untouched.
Graduate student Yi Li, the study's lead author, explained the elegant logic: "There's only one amino acid change between the wild-type and the disease-causing phenotype, and that's why we used the antibody to recognize which is which." The condensates work by incorporating a proteasome-targeting motif—essentially a "trash tag" that tells the cell's waste disposal system to break down the marked proteins. Unlike conventional delivery vehicles, these synthetic condensates preserve antibody activity, recruit the proteasome directly, and ensure uniform delivery across different cell types.
The results were striking. In cell cultures, the system selectively eliminated the KRAS G12V mutation without harming normal proteins. More importantly, when tested in a mouse model carrying the KRAS G12V mutation, the approach suppressed tumor growth—a crucial demonstration that the therapy works in living organisms, not just in laboratory dishes.
The implications extend far beyond KRAS. Because antibodies are abundant and diverse, researchers believe this platform could target virtually any intracellular disease-causing protein. Cancer-driving mutations, neurodegenerative disease proteins, and genetic disorder culprits could all theoretically be eliminated using the same fundamental approach, customized with different antibodies.
Looking ahead, the Northwestern team is investigating even broader possibilities. Yi Li noted that while cell biologists understand how cells naturally create and manage membrane-less organelles, the interaction between these artificial condensates and living cells remains largely unexplored. Future work aims to engineer therapeutic condensates that do more than simply deliver cargo—they could perform cell-like functions after entering the cell, such as targeted protein disposal, molecular sequestration, and intracellular cargo reallocation. "Biomolecular condensates may represent a new class of programmable biomaterials," Li said, suggesting this discovery opens a door to an entirely new category of cell-mimicking therapeutics.